108 related articles for article (PubMed ID: 30668187)
21. Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
Kim K; McMillin GA; Bernard PS; Tantravahi S; Walker BS; Schmidt RL
PLoS One; 2019; 14(12):e0226552. PubMed ID: 31869360
[TBL] [Abstract][Full Text] [Related]
22. How could patient reported outcomes improve patient management in chronic myeloid leukemia?
De Marchi F; Medeot M; Fanin R; Tiribelli M
Expert Rev Hematol; 2017 Jan; 10(1):9-14. PubMed ID: 27858461
[TBL] [Abstract][Full Text] [Related]
23. The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios.
Franken MG; Corro Ramos I; Los J; Al MJ
BMC Fam Pract; 2018 Feb; 19(1):31. PubMed ID: 29454331
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
[TBL] [Abstract][Full Text] [Related]
25. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
26. Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pandor A; Stevenson M; Stevens J; James MM; Hamilton J; Byrne J; Rudin C; Rawdin A; Wong R
Pharmacoeconomics; 2018 Aug; 36(8):903-915. PubMed ID: 29480454
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology of chronic myeloid leukaemia (CML).
Rohrbacher M; Hasford J
Best Pract Res Clin Haematol; 2009 Sep; 22(3):295-302. PubMed ID: 19959081
[TBL] [Abstract][Full Text] [Related]
28. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.
Wu EQ; Johnson S; Beaulieu N; Arana M; Bollu V; Guo A; Coombs J; Feng W; Cortes J
Curr Med Res Opin; 2010 Jan; 26(1):61-9. PubMed ID: 19905880
[TBL] [Abstract][Full Text] [Related]
29. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
31. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
Breccia M; Efficace F; Sica S; Abruzzese E; Cedrone M; Turri D; Gobbi M; Carella AM; Gozzini A; Usala E; Cavazzini F; Danise P; Tiribelli M; Binotto G; Pregno P; Bocchia M; Gaidano G; Crugnola M; Bonifacio M; Avanzini P; Celesti F; Guella A; Martino B; Annunziata M; Luciano L; Stagno F; Vallisa D; Pungolino E; Iurlo A; Rambaldi A; Nardiello I; Orlandi E; Gambacorti-Passerini C; Alimena G
Leuk Res; 2015 Oct; 39(10):1055-9. PubMed ID: 26282944
[TBL] [Abstract][Full Text] [Related]
32. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
[TBL] [Abstract][Full Text] [Related]
33. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.
McCarberg BH
Postgrad Med; 2011 Nov; 123(6):132-9. PubMed ID: 22104462
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
35. Medical decision analysis for first-line therapy of chronic myeloid leukemia.
Rochau U; Sroczynski G; Wolf D; Schmidt S; Conrads-Frank A; Jahn B; Saverno K; Brixner D; Radich J; Gastl G; Siebert U
Leuk Lymphoma; 2014 Aug; 55(8):1758-67. PubMed ID: 24160847
[TBL] [Abstract][Full Text] [Related]
36. Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase.
Schrover RJ; Adena MA; De Abreu Lourenco R; Prince HM; Seymour JF; Wonder MJ
Leuk Lymphoma; 2006 Jun; 47(6):1069-81. PubMed ID: 16840199
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
[TBL] [Abstract][Full Text] [Related]
38. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study.
Zafari Z; Lynd LD; FitzGerald JM; Sadatsafavi M
J Allergy Clin Immunol; 2014 Oct; 134(4):908-915.e3. PubMed ID: 24875619
[TBL] [Abstract][Full Text] [Related]
39. The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms.
Moulin SM; Eutrópio FJ; Souza JO; Busato FO; Olivieri DN; Tadokoro CE
Support Care Cancer; 2017 Mar; 25(3):951-955. PubMed ID: 27866336
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]